X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (40204) 40204
Newspaper Article (2901) 2901
Newsletter (1049) 1049
Magazine Article (333) 333
Book Chapter (322) 322
Trade Publication Article (41) 41
Publication (24) 24
Transcript (19) 19
Book / eBook (15) 15
Web Resource (12) 12
Dissertation (10) 10
Conference Proceeding (7) 7
Reference (5) 5
Government Document (4) 4
Report (3) 3
Book Review (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (32617) 32617
science & technology (26969) 26969
life sciences & biomedicine (26210) 26210
anticoagulants (20995) 20995
male (16424) 16424
anticoagulants - administration & dosage (16402) 16402
female (16183) 16183
anticoagulants - therapeutic use (12932) 12932
aged (11097) 11097
middle aged (11078) 11078
cardiovascular system & cardiology (9140) 9140
anticoagulants - adverse effects (8929) 8929
adult (7409) 7409
risk factors (7050) 7050
administration, oral (6359) 6359
treatment outcome (6359) 6359
abridged index medicus (5588) 5588
cardiac & cardiovascular systems (5419) 5419
hematology (5282) 5282
peripheral vascular disease (4825) 4825
warfarin (4733) 4733
aged, 80 and over (4609) 4609
thrombosis (4314) 4314
atrial fibrillation (4305) 4305
thromboembolism (4304) 4304
stroke (4213) 4213
general & internal medicine (4143) 4143
warfarin - administration & dosage (4078) 4078
surgery (3909) 3909
drug therapy (3765) 3765
care and treatment (3713) 3713
animals (3700) 3700
heparin - administration & dosage (3683) 3683
retrospective studies (3633) 3633
pharmacology & pharmacy (3632) 3632
hemorrhage - chemically induced (3629) 3629
patients (3484) 3484
time factors (3395) 3395
medicine, general & internal (3329) 3329
heparin (3297) 3297
dosage and administration (3212) 3212
atrial fibrillation - drug therapy (3177) 3177
analysis (3044) 3044
research (2969) 2969
anticoagulants - pharmacology (2964) 2964
warfarin - therapeutic use (2774) 2774
medicine & public health (2757) 2757
health aspects (2610) 2610
prospective studies (2610) 2610
stroke - prevention & control (2527) 2527
heparin - therapeutic use (2508) 2508
international normalized ratio (2475) 2475
anticoagulation (2472) 2472
warfarin - adverse effects (2466) 2466
thromboembolism - prevention & control (2416) 2416
dose-response relationship, drug (2343) 2343
mortality (2338) 2338
blood coagulation - drug effects (2284) 2284
atrial fibrillation - complications (2215) 2215
cardiology (2214) 2214
risk assessment (2200) 2200
cardiac arrhythmia (2196) 2196
prevention (2111) 2111
follow-up studies (2101) 2101
heparin - adverse effects (2018) 2018
hemorrhage (2004) 2004
clinical trials (1999) 1999
bleeding (1944) 1944
drug administration schedule (1832) 1832
adolescent (1792) 1792
medical research (1770) 1770
rivaroxaban (1751) 1751
venous thromboembolism (1751) 1751
glycosaminoglycans (1743) 1743
complications and side effects (1676) 1676
usage (1645) 1645
drug therapy, combination (1641) 1641
thrombin (1637) 1637
drug dosages (1633) 1633
platelet aggregation inhibitors - therapeutic use (1628) 1628
thrombosis - prevention & control (1621) 1621
internal medicine (1609) 1609
venous thromboembolism - prevention & control (1573) 1573
dabigatran (1560) 1560
stroke - etiology (1552) 1552
studies (1550) 1550
anticoagulants - pharmacokinetics (1520) 1520
incidence (1493) 1493
venous thrombosis - drug therapy (1486) 1486
pregnancy (1462) 1462
fibrinolytic agents - therapeutic use (1459) 1459
heparin, low-molecular-weight - therapeutic use (1457) 1457
pulmonary embolism (1446) 1446
medicine (1415) 1415
platelet aggregation inhibitors - administration & dosage (1410) 1410
heparin, low-molecular-weight - administration & dosage (1404) 1404
neurosciences & neurology (1404) 1404
drug interactions (1399) 1399
aspirin (1397) 1397
randomized controlled trials as topic (1377) 1377
more...
Library Location Library Location
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (42050) 42050
German (1117) 1117
French (653) 653
Japanese (399) 399
Russian (396) 396
Spanish (391) 391
Italian (205) 205
Portuguese (116) 116
Chinese (95) 95
Polish (94) 94
Hungarian (89) 89
Swedish (80) 80
Danish (76) 76
Norwegian (73) 73
Dutch (63) 63
Czech (52) 52
Turkish (38) 38
Finnish (15) 15
Ukrainian (15) 15
Bulgarian (14) 14
Romanian (14) 14
Hebrew (13) 13
Serbian (13) 13
Lithuanian (11) 11
Croatian (9) 9
Korean (6) 6
Icelandic (3) 3
Arabic (2) 2
Persian (2) 2
Slovak (2) 2
Bosnian (1) 1
Urdu (1) 1
Welsh (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


The New England journal of medicine, ISSN 1533-4406, 03/2017, Volume 376, Issue 13, pp. 1211 - 1222
Journal Article
Journal of the American College of Cardiology, ISSN 0735-1097, 09/2014, Volume 64, Issue 11, pp. 1128 - 1139
Journal Article
Journal of thrombosis and haemostasis, ISSN 1538-7933, 09/2018, Volume 16, Issue 9, pp. 1891 - 1894
Peripheral Vascular Disease | Life Sciences & Biomedicine | Hematology | Cardiovascular System & Cardiology | Science & Technology | Recurrence | Pulmonary Embolism - prevention & control | Pyrazoles - therapeutic use | Dabigatran - administration & dosage | Prospective Studies | Anticoagulants - administration & dosage | Humans | Thiazoles - administration & dosage | Antithrombins - administration & dosage | Thiazoles - therapeutic use | Dabigatran - therapeutic use | Rivaroxaban - administration & dosage | Venous Thromboembolism - drug therapy | Factor Xa Inhibitors - administration & dosage | Neoplasms - complications | Pyridones - administration & dosage | Venous Thromboembolism - prevention & control | Multicenter Studies as Topic | Neoplasms - blood | Dalteparin - therapeutic use | Observational Studies as Topic | Venous Thrombosis - prevention & control | Rivaroxaban - therapeutic use | Pyridines - therapeutic use | Pyridines - administration & dosage | Venous Thrombosis - drug therapy | Administration, Oral | Antithrombins - therapeutic use | Anticoagulants - therapeutic use | Anticoagulants - adverse effects | Venous Thrombosis - etiology | Randomized Controlled Trials as Topic | Venous Thromboembolism - etiology | Factor Xa Inhibitors - therapeutic use | Pyrazoles - administration & dosage | Patient Acceptance of Health Care | Pulmonary Embolism - etiology | Antithrombins - adverse effects | Factor Xa Inhibitors - adverse effects | Pulmonary Embolism - drug therapy | Pyridones - therapeutic use | Hemorrhage - chemically induced | Care and treatment | Anticoagulants (Medicine) | Thromboembolism | Drug therapy | Cancer | Anticoagulants | Index Medicus
Journal Article
British journal of clinical pharmacology, ISSN 0306-5251, 09/2013, Volume 76, Issue 3, pp. 455 - 466
.../2J2 , P ‐gp and Bcrp ( ABCG2 ). However, the pharmacokinetic effects and implications of the co‐administration of rivaroxaban and medications that interfere... 
P‐glycoprotein | rivaroxaban | drug interactions | cytochrome P450 | healthy subjects | P-glycoprotein | Rivaroxaban | Healthy subjects | Cytochrome P450 | Drug interactions | Life Sciences & Biomedicine | Pharmacology & Pharmacy | Science & Technology | Anticoagulants - administration & dosage | Cytochrome P-450 Enzyme Inhibitors | Erythromycin - pharmacology | Ketoconazole - administration & dosage | Humans | Middle Aged | Cytochrome P-450 Enzyme System - metabolism | Midazolam - administration & dosage | Substrate Specificity | Metabolic Clearance Rate | Thiophenes - administration & dosage | Ketoconazole - pharmacology | Enzyme Inhibitors - administration & dosage | Young Adult | Drug Interactions | Enzyme Inhibitors - pharmacokinetics | Clarithromycin - pharmacokinetics | Clarithromycin - administration & dosage | Adult | Morpholines - administration & dosage | Enzyme Inhibitors - pharmacology | Ketoconazole - pharmacokinetics | Midazolam - pharmacokinetics | Cytochrome P-450 CYP3A - administration & dosage | Erythromycin - administration & dosage | ATP Binding Cassette Transporter, Subfamily B, Member 1 - antagonists & inhibitors | ATP Binding Cassette Transporter, Subfamily B, Member 1 - metabolism | Thiophenes - pharmacokinetics | Erythromycin - pharmacokinetics | Cytochrome P-450 CYP3A - metabolism | Adolescent | Anticoagulants - pharmacokinetics | Morpholines - pharmacokinetics | Clarithromycin - pharmacology | Midazolam - pharmacology | Ketoconazole | Protease inhibitors | Fluconazole | Proteases | Cytochrome P-450 | Dosage and administration | Anticoagulants (Medicine) | Erythromycin | Thromboembolism | Index Medicus
Journal Article
International Journal of Cardiology, ISSN 0167-5273, 2014, Volume 179, pp. 279 - 287
Journal Article
Thrombosis and Haemostasis, ISSN 0340-6245, 01/2009, Volume 101, Issue 1, pp. 77 - 85
Dabigatran etexilate has been investigated in three phase III trials for the prevention of venous thromboembolism (VTE). Health technology assessment agencies... 
anticoagulants | thrombosis | prophylaxis | Embolism | Meta-analysis | Anticoagulants | Thrombosis | Prophylaxis | Peripheral Vascular Disease | Life Sciences & Biomedicine | Hematology | Cardiovascular System & Cardiology | Science & Technology | Venous Thromboembolism - mortality | Anticoagulants - administration & dosage | Arthroplasty, Replacement, Knee - adverse effects | Humans | Dabigatran | Enoxaparin - therapeutic use | Enoxaparin - adverse effects | Venous Thromboembolism - prevention & control | Clinical Trials, Phase III as Topic | Enoxaparin - administration & dosage | Pyridines - adverse effects | Benzimidazoles - administration & dosage | Benzimidazoles - adverse effects | Benzimidazoles - therapeutic use | Pyridines - therapeutic use | Pyridines - administration & dosage | Drug Administration Schedule | Risk Assessment | Administration, Oral | Anticoagulants - therapeutic use | Treatment Outcome | Anticoagulants - adverse effects | Arthroplasty, Replacement, Hip - adverse effects | Venous Thromboembolism - etiology | Hemorrhage - chemically induced | Index Medicus | Administration | Phase III as Topic | Benzimidazoles/administration & dosage/adverse effects/therapeutic use | Pyridines/administration & dosage/adverse effects/therapeutic use | Arthroplasty | Replacement | Oral | Clinical Trials | Kirurgi | Knee/adverse effects | Hemorrhage/chemically induced | Venous Thromboembolism/etiology/mortality/prevention & control | Hip/adverse effects | Anticoagulants/administration & dosage/adverse effects/therapeutic use | Surgery | Enoxaparin/administration & dosage/adverse effects/therapeutic use
Journal Article
Stroke (1970), ISSN 1524-4628, 06/2013, Volume 44, Issue 6, pp. 1676 - 1681
Background and Purpose-To estimate the cost-effectiveness of stroke prevention in patients with nonvalvular atrial fibrillation by using novel oral... 
Intracranial hemorrhage | Stroke | Anticoagulation | Markov model | Cost-effectiveness | Atrial fibrillation | Clinical Neurology | Peripheral Vascular Disease | Neurosciences & Neurology | Life Sciences & Biomedicine | Cardiovascular System & Cardiology | Science & Technology | Thiophenes - therapeutic use | Markov Chains | Pyrazoles - therapeutic use | Anticoagulants - administration & dosage | United States | Humans | Anticoagulants - economics | Thiophenes - administration & dosage | Warfarin - economics | Benzimidazoles - economics | Dabigatran | Morpholines - economics | Warfarin - administration & dosage | Warfarin - therapeutic use | Dose-Response Relationship, Drug | Pyridones - administration & dosage | Rivaroxaban | Benzimidazoles - administration & dosage | beta-Alanine - economics | Stroke - epidemiology | Thiophenes - economics | Pyridones - economics | beta-Alanine - analogs & derivatives | Morpholines - therapeutic use | Benzimidazoles - therapeutic use | Quality-Adjusted Life Years | Stroke - prevention & control | Administration, Oral | Morpholines - administration & dosage | Risk Factors | Atrial Fibrillation - complications | beta-Alanine - administration & dosage | beta-Alanine - therapeutic use | Anticoagulants - therapeutic use | Models, Statistical | Pyrazoles - economics | Pyrazoles - administration & dosage | Cost-Benefit Analysis | Aged | Pyridones - therapeutic use | Cohort Studies | Index Medicus
Journal Article